El interés en corto de iShares Gold Trust Micro Shares da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de iShares Gold Trust Micro Shares. Los datos de interés en corto se actualizan cada dos semanas.

iShares Gold Trust Micro Shares (ARCA:IAUM), Informe de interés en corto

The Trust seeks to reflect such performance before payment of the Trusts expenses and liabilities. The Shares are intended to constitute a simple and cost-effective means of making an investment similar to an investment in gold. An investment in physical gold requires expensive and sometimes complicated arrangements in connection with the assay, transportation, warehousing and insurance of the metal

iShares Gold Trust Micro ETF

iShares Gold Trust Micro Shares

Silexion Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer. The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan—two main components commonly used in pancreatic cancer treatments—when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer. Moreover, synergistic activity was also observed with the chemotherapeutic agent gemcitabine.
This promising synergistic activity was observed after the confluence of these tumor cell lines, reflecting how SIL-204 may enhance the effects of 5-fluorouracil and irinotecan when used together, as well as that of gemcitabine. For example, in preclinical models, the combination of 5-fluorouracil and irinotecan with SIL-204 led to a significant reduction in cancer cell confluence after about three days compared to treatment with the chemotherapy agents alone (p &lt; 0.0005), further supporting the synergistic potential of SIL-204 in enhancing standard chemotherapy treatments. This comes on top of previous recent announcements from Silexion regarding pre-clinical findings from the ongoing development of SIL-204, in line with earlier successes with the company's first-generation product, LODER&#x2122; (siG12DLoder), which showed a significant improvement in overall survival in the siRNA plus chemotherapy arm compared to chemotherapy alone in Phase 2 trials.

Biotech

News

General

SLXN

Silexion Therapeutics Reports Additional Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

Powell Max Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) (the "Company" or "Powell Max"), a financial communications services provider headquartered in Hong Kong, today announced that it has commenced activities to pursue acquisitions as part of its strategy to build and grow its business operations. The Company is currently evaluating several other financial communications service companies to continue its growth and enhance its market share in the financial communications industry in Hong Kong and Asia.
Powell Max intends to acquire companies that are generating between $1.5 million and $5 million in gross annual revenue. &nbsp;The Company intends to retain most of the management teams of the acquired companies and to expand those teams to include additional management professionals specializing in corporate strategy and business development. The acquired companies will be allowed to operate semi-autonomously as separate business units under their respective managements, and &nbsp;management personnel of each unit will be under the direct supervision of the top management of the Company. By acquiring other competitors in the financial communications business, Powell Max is looking to further develop its clientele and achieve economies of scale.

Global

PMAX

Powell Max Announced Acquisition Plans Targeting $1.5M-$5M Revenue Firms To Expand In Hong Kong And Asia Financial Communications Market

5 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.8, a high estimate of $77.00, and a low estimate of $60.00. This current average represents a 2.37% decrease from the previous average price target of $67.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974858_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Ionis Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Allison Bratzel</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ionis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Ionis Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ionis Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Ionis Pharmaceuticals Better</h2>
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
<h3>Ionis Pharmaceuticals: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Ionis Pharmaceuticals's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -7.21% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -104.98%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.34%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.87%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.18, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

IONS

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts

Ratings for NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for NeoGenomics, revealing an average target of $19.6, a high estimate of $22.00, and a low estimate of $19.00. Observing a 4.53% increase, the current average has risen from the previous average price target of $18.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974850_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NeoGenomics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NeoGenomics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NeoGenomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know NeoGenomics Better</h2>
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
<h3>Understanding the Numbers: NeoGenomics's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: NeoGenomics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.44%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): NeoGenomics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.08%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NeoGenomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess NeoGenomics: What You Need To Know

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, and a low estimate of $14.00. Experiencing a 19.71% decline, the current average is now lower than the previous average price target of $24.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974842_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of 10x Genomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 10x Genomics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into 10x Genomics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TXG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on 10x Genomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About 10x Genomics</h2>
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
<h3>10x Genomics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, 10x Genomics faced challenges, resulting in a decline of approximately -1.3% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: 10x Genomics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -23.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): 10x Genomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.83%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: 10x Genomics's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts

TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average annual return of 24.7%. Currently, TransMedics Gr has a market capitalization of $2.13 billion. 
Buying $100 In TMDX: If an investor had bought $100 of TMDX stock 5 years ago, it would be worth $301.53 today based on a price of $63.50 for TMDX at the time of writing.
<h3>TransMedics Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736974841_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TMDX

Here's How Much You Would Have Made Owning TransMedics Gr Stock In The Last 5 Years

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sight Sciences and provided 12-month price targets. The average target is $4.72, accompanied by a high estimate of $5.50 and a low estimate of $3.00. Experiencing a 20.67% decline, the current average is now lower than the previous average price target of $5.95. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974833_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Sight Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.60</td>
<td>$5.80</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sight Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sight Sciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Sight Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SGHT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sight Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Sight Sciences</h2>
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
<h3>Sight Sciences's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Sight Sciences showcased positive performance, achieving a revenue growth rate of 0.74% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sight Sciences's net margin excels beyond industry benchmarks, reaching -54.9%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sight Sciences's ROE excels beyond industry benchmarks, reaching -11.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sight Sciences's ROA excels beyond industry benchmarks, reaching -7.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Sight Sciences's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SGHT

Expert Outlook: Sight Sciences Through The Eyes Of 5 Analysts

11 analysts have expressed a variety of opinions on Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Deere, revealing an average target of $480.18, a high estimate of $550.00, and a low estimate of $430.00. Witnessing a positive shift, the current average has risen by 5.7% from the previous average price target of $454.27.
<img src="https://www.benzinga.com/files/images/story/2025/1736974822_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Deere. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$470.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$538.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$470.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Stephen Volkmann</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$510.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$401.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$462.00</td>
<td>$404.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$538.00</td>
<td>$496.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$477.00</td>
<td>$448.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$450.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$475.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Deere. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Deere compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Deere's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Deere's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Deere analyst ratings.</a>
<h2>Unveiling the Story Behind Deere</h2>
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
<h3>Financial Insights: Deere</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Deere's financials over 3 months reveals challenges. As of 31 October, 2024, the company experienced a decline of approximately -28.57% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Deere's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.5%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Deere's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.43% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Deere's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Deere's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deere Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Analysts' ratings for Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Charter Communications and provided 12-month price targets. The average target is $402.27, accompanied by a high estimate of $500.00 and a low estimate of $315.00. This current average has increased by 6.0% from the previous average price target of $379.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736974813_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Charter Communications is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$380.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kohulan Paramaguru</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Bryan Kraft</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$365.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$390.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Sebastiano Petti</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Jessica Ehrlich</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$385.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Charter Communications. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Charter Communications compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Charter Communications's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Charter Communications's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charter Communications analyst ratings.</a>
<h2>Discovering Charter Communications: A Closer Look</h2>
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 58 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
<h3>Charter Communications: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Charter Communications displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.55%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Charter Communications's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.28%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Charter Communications's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Charter Communications's ROA excels beyond industry benchmarks, reaching 0.86%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 6.83, Charter Communications faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHTR

Assessing Charter Communications: Insights From 11 Financial Analysts

Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) has outperformed the market over the past 5 years by 2.63% on an annualized basis producing an average annual return of 14.99%. Currently, Wheaton Precious Metals has a market capitalization of $26.17 billion. 
Buying $100 In WPM: If an investor had bought $100 of WPM stock 5 years ago, it would be worth $201.09 today based on a price of $57.70 for WPM at the time of writing.
<h3>Wheaton Precious Metals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736974791_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Wheaton Precious Metals 5 Years Ago Would Be Worth Today

<a href="https://patentcenter.uspto.gov/applications/16951317/ifw/docs">https://patentcenter.uspto.gov/applications/16951317/ifw/docs</a>
&nbsp;
<figure class="image"><img src="https://pbs.twimg.com/media/GhXLe8RbYAESITU?format=jpg&amp;name=small" alt="Image" /></figure><figure class="image"><img src="https://pbs.twimg.com/media/GhXLe8PaMAA5mLE?format=jpg&amp;name=360x360" alt="Image" /></figure><figure class="image"><img src="https://pbs.twimg.com/media/GhXLe8Ra8AEp8Fj?format=jpg&amp;name=small" alt="Image" /></figure>

AMIX

Autonomix Medical Has Received A Notice Of Allowance For A U.S. Patent Titled "Smart Torquer And Methods Of Using The Same (For Engaging Intravascular Devices, Such As Guide Wires Or Catheters, During Surgery)"

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock is trading higher on Wednesday amid recent data from Kelley Blue Book, which ranked some of Tesla&#8217;s electric vehicles among the top of its, &#8220;10 Best-Selling EVs in 2024&#8221; list.
The Details: The automotive research company <a href="https://www.kbb.com/car-news/america-set-ev-sales-record-in-2024/">ranked</a> Tesla&#8217;s Model Y and Model 3 as the best and second best-selling electric vehicles. However, Kelley Blue Book noted that Tesla sold about 37,000 fewer cars in 2024 compared to 2023.
Kelley Blue Book attributed the lost ground to more competitors entering the market. Tesla sold approximately 37,000 fewer vehicles; meanwhile, General Motors saw a similar increase in volume.
Tesla&#8217;s Cybertruck ranked number five on the best-selling list. Some other vehicles that made the list include Ford&#8217;s Mustang Mach-E, Chevrolet&#8217;s Equinox and Hyundai&#8217;s IONIQ 5.
In 2024, electric vehicles made up 8.7% of all new cars sold, and Kelley Blue Book&#8217;s parent company, Cox Automotive, predicts further growth in 2025. The company forecasts that factors such as an improved charging infrastructure could boost electric vehicle sales and account for 10% or more of new cars sold. 
Notably, President-elect Donald Trump has stated that he may seek to eliminate the $7,500 tax rebate on electric vehicle purchases, though achieving this would require approval from Congress.
See Also: <a href="https://www.benzinga.com/insights/analyst-ratings/25/01/43012883/breaking-down-lands-end-7-analysts-share-their-views">Breaking Down Lands&#8217; End: 7 Analysts Share Their Views</a>
TSLA Price Action: At the time of writing, Tesla stock is trading 8.04% higher at $428.08, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Tesla

Movers

TSLA

What's Going On With Tesla Shares Wednesday?

Investors and analysts could turn attention to how UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) will replace its insurance unit CEO Brian Thompson, who was fatally shot in December, and how the company will keep public trust as the sector comes under increased scrutiny when the company reports fourth-quarter financial results before <a href="https://www.benzinga.com/earnings">market open Thursday.</a>
Earnings Estimates: Analysts expect UnitedHealth to report fourth-quarter revenue of $101.75 billion, up from $94.43 billion in last year's fourth quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has missed analyst revenue estimates in two straight quarters, while beating estimates in eight of the last 10 quarters.
Analysts expect the company to report fourth-quarter earnings per share of $6.73, up from $6.16 in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters.
Read Also: <a href="https://www.benzinga.com/general/health-care/25/01/43001214/unitedhealth-the-number-one-company-on-sale-ahead-of-q4-earnings-report">UnitedHealth: The &#8216;Number One Company On Sale&#8217; Ahead Of Q4 Earnings Report</a>
Key Items to Watch: Thursday's earnings report marks the first quarterly report from UnitedHealth since the company lost Thompson.
Thompson, who was the CEO of UnitedHealthcare, was <a href="https://www.benzinga.com/general/health-care/24/12/42316904/unitedhealthcare-ceo-brian-thompson-fatally-shot-outside-nyc-hotel">shot and killed </a>on Dec. 4 in New York City. Luigi Mangione was arrested for the murder and is facing state and federal charges that include<a href="https://www.benzinga.com/24/12/42605759/luigi-mangione-faces-death-penalty-details-show-attack-planned-for-months-the-target-is-insuranceit-checks-every-box"> first degree murder.</a> Mangione faces potential sentences of life in prison without parole and the possibility of the death penalty if found guilty.
Analysts and investors may be ready to hear if UnitedHealth will address the challenges of replacing Thompson and moving forward after his passing. Sources told <a href="https://www.bloomberg.com/news/articles/2025-01-15/ceo-brian-thompson-s-death-looms-over-unitedhealth-earnings-call?sref=TBDibEcD">Bloomberg </a>the company is not ready to immediately replace Thompson.
UnitedHealth Group CEO Andrew Witty<a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings"> recently reportedly told </a>executives the company will hit financial records in the current fiscal year, which could put the company and stock back in the spotlight a month after Thompson's death.
The company's revenue through the first nine months is $299 billion, a company record, and up from $277 billion through the first nine months of 2023.
Health insurance companies like UnitedHealth have come under increased attention and pressure after Thompson's death. A notebook found on Mangione at the time of his arrest mentioned how insurance companies were focused on profits over the public's health.
An entry in the notebook dated Aug. 15 said: "The details are finally coming together." The entry said procrastination had allowed Mangione to learn more about the company he was targeting; the name of the company was redacted.
"The target is insurance…it checks every box," was also written in the notebook alleged to belong to Mangione, according to the federal complaint against him.
Despite being on trial for murder, Mangione has gained a level of public support, with Thompson's death becoming a rallying cry for critics of the health insurance industry, often accused of denying medical claims.
Along with navigating the fallout from Thompson's death and the increased attention on insurance claims, UnitedHealth has found itself a target of incoming President Donald Trump, who<a href="https://www.benzinga.com/24/12/42517567/cvs-cigna-unitedhealth-shares-slide-as-trump-targets-drug-middleman"> recently spoke out</a> about pharmacy benefit managers.
Trump said he would "knock out" PBMs from the industry, referring to them as drug middlemen, a role they are commonly associated with.
"You know the middleman, right? The horrible middleman that makes more money frankly than the drug companies, and they don't do anything except they're a middleman. We're going to knock out the middleman," Trump said.
UnitedHealth is also facing bipartisan pressure from Congress to push for the breakup of health care conglomerates over PBM practices.
The insurance company also faces scrutiny from the Department of Justice, which has blocked United's $3.3 billion <a href="https://www.benzinga.com/24/12/42704893/amedisys-and-unitedhealth-extend-merger-deadline-whats-going-on">deal to acquire </a>Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
Along with any commentary on how the new White House administration and public pressure could impact the company's future growth and operations, investors and analysts may be looking for an update on guidance.
UnitedHealth <a href="https://www.benzinga.com/general/health-care/24/12/42317793/unitedhealth-introduces-2025-guidance-ahead-of-now-stopped-investor-conference">shared 2025 revenue guidance </a>of $450 billion to $455 billion and earnings per share guidance of $28.15 to $28.65 ahead of Thompson's death in December.
UNH, DIA Price Action: UnitedHealth stock trades at $544.11 versus a 52-week trading range of $436.38 to $630.73. UnitedHealth stock is up 4.8% over the last year, but has fallen around 11% since Thompson's death.
The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) and other ETFs that track the Dow Jones Industrial Average will also be in the spotlight Thursday after UnitedHealth's report. United is the second largest component of the Dow Jones Index due to its price-weighted methodology.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42544499/luigi-mangione-documentaries-in-the-works-from-award-winning-creators-and-possibly-rapper-50-cent">Luigi Mangione Documentaries In The Works From Award-Winning Creators — And Possibly Rapper 50 Cent</a></li>
</ul>
Photo: Shutterstock

Previews

AMED

SPDR Dow Jones Industrial Average ETF Trust

UnitedHealth Group Q4 Earnings Preview: First Report Since Insurance CEO's Murder Comes With Questions On Company's Future

WIIM

SPOT

Spotify shares are trading higher after UBS raised its price target on the stock from $485 to $540.

Caret Digital has commenced mining with initial fleet of Antminer L9s&nbsp;
Further mining rigs to be ordered and deployed on a staged basis at hosting facilities in Wisconsin and Oregon
LONDON, Jan. 15, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) (&quot;VivoPower&quot; or the &quot;Company&quot;) announced today that its wholly owned subsidiary, Caret LLC (trading as &quot;Caret Digital&quot;), has commenced Dogecoin mining operations with an initial fleet of Antminer L9 rigs at its Wisconsin hosting facility.
Execution of this strategy will allow Caret Digital to take advantage of the current profitability of Dogecoin mining to generate revenues and free cashflows for VivoPower as a group. Caret Digital does not intend to hold most of the Dogecoin that is mined but will sell or forward sell them as appropriate. Based on current Dogecoin prices and Antminer GPU costs, there is potential for Caret Digital to generate annual revenues of up to US$25m and cash EBITDA of up to $12m (although this is subject to signification variation given the volatility of both price and cost variables, and should not be taken as a forecast). VivoPower intends to use any free cashflow generated from the Dogecoin mining operations to reinvest into its Tembo e-LV business, and further its commitment to delivering on the triple bottom line of people, profit and planet.
At the same time, Caret Digital will continue to work on developing up to 55MW of its own renewable-powered mining capacity to be used for Dogecoin and Litecoin mining, as previously announced. With a 55MW facility, Caret Digital would be able to generate revenues of up to $150m per annum from Dogecoin mining (based on current price and cost inputs, which are subject to significant variability and hence this should not be taken as a forecast).

&nbsp;

VVPR

VivoPower's Caret Digital Commences Dogecoin Mining Operations In Wisconsin; Caret Digital To Generate Up To $25M Revenue, $12M Cash EBITDA From Dogecoin Mining; Plans 55MW Renewable Capacity For $150M Annual Revenue; VivoPower To Reinvest Proceeds Into Tembo e-LV Business

Entegris's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NYSE">ENTG</a>) short percent of float has risen 3.17% since its last report. The company recently reported that it has 7.35 million shares sold short, which is 4.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Entegris Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736973921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Entegris has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Entegris's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Entegris's peer group average for short interest as a percentage of float is 9.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ENTG

How Is The Market Feeling About Entegris?

Powell Industries's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NYSE">POWL</a>) short percent of float has fallen 17.88% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 17.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Powell Industries Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736973916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Powell Industries has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Powell Industries's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Powell Industries's peer group average for short interest as a percentage of float is 10.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

POWL

How Is The Market Feeling About Powell Industries?

KB Home's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) short percent of float has fallen 3.73% since its last report. The company recently reported that it has 5.39 million shares sold short, which is 11.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KB Home Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736973911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KB Home has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KB Home's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KB Home's peer group average for short interest as a percentage of float is 10.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About KB Home?

Cryptocurrency markets are surging on Wednesday as financial markets interpreted freshly-released inflation data as a positive sign for equities.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$100,135.47</td>
<td>+4%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,456.54</td>
<td>+7.9%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$202.23</td>
<td>+8.9%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.94</td>
<td>+11%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.3773</td>
<td>+7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002235</td>
<td>+4.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 25.6% and daily active addresses up by 6%. Transactions greater than $100,000 are down from 10,421 to 10,217 in a single day. Exchanges netflows are down by 132.8%.</li>
<li>Coinglass data reports 100,006 traders were liquidated in the past 24 hours for $266.75 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43001690/exclusive-crypto-commodities-take-center-stage-volatility-2025-direxion-ceo">EXCLUSIVE: Direxion CEO Predicts Crypto, Commodities Will Take Center Stage Amid Volatility In 2025</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008361/dubai-announces-crypto-tower-to-host-blockchain-businesses">Dubai Announces &#8216;Crypto Tower&#8217; To Host Blockchain Businesses</a></li>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42997294/trumps-crypto-legislation-will-be-a-frankenstein-bill-of-mishmash-says-arthur-hayes-bitcoin-doesnt-need-government-support-to-flourish">Trump&#8217;s Crypto Legislation Will Be A &#8216;Frankenstein&#8217; Bill Of Mishmash, Says Arthur Hayes — Bitcoin Doesn&#8217;t Need Government Support To Flourish</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008666/sec-under-trump-administration-to-revise-crypto-policies-report">SEC Under Trump Administration To Revise Crypto Policies: Report</a></li>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42994641/italys-largest-bank-leaps-into-bitcoin-trading-with-1-million-test-investment-but-ceo-says-he-doesnt-invest-in-btc-personally">Italy&#8217;s Largest Bank Leaps Into Bitcoin Trading With $1 Million &#8216;Test&#8217; Investment But CEO Says He Doesn&#8217;t Invest In BTC Personally</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42993667/ripple-labs-donates-100k-in-xrp-for-california-wildfires-relief-says-contributions-will-be-doubled">Ripple Labs Donates $100K In XRP For California Wildfires Relief, Says Contributions Will Be Doubled</a></li>
</ul>
Top Gainer:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td> $3.90</td>
<td>+31.5%</td>
</tr>
<tr>
<td>ai16z (CRYPTO: AI16Z)</td>
<td> $1.61</td>
<td>+25.7%</td>
</tr>
<tr>
<td>XDC Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">XDC</a>)</td>
<td> $0.1304</td>
<td>+23.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices touching $100,000, CryptoCon provided technical analysis for the crypto king stating that 5.618 extension of the first move of the cycle has had a near-perfect hit rate for all major Bitcoin highs. 
He sees Bitcoin&#8217;s price target at $184,181.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The 5.618 extension of the first move of the cycle (candle body &amp; after bear market downtrend) has had a near-perfect hit rate for all major Bitcoin highs. The magic number this cycle&#8230; $184,181. <a href="https://t.co/p6CgSQTvyB">pic.twitter.com/p6CgSQTvyB</a>
&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1879614951813271733?ref_src=twsrc%5Etfw">January 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto content creator Michael Pizzino <a href="https://x.com/PizzinoMichael/status/1879621062197166149">welcomes</a> back $100,000 and expects a higher low, saying &#8220;Off to the races.&#8221; However, this will need a few days to form if it is to happen right now.
Stoic sees Bitcoin having experienced a clean breakout from its value area, followed by a reaction near the high $80,000 and a successful reclaim of the $90,000 level.
 Currently, a brief period of cooling off is anticipated in the interim, with attention focused on finding spot support on the buyside.
A <a href="https://x.com/Stoiiic/status/1879589287290683441">pullback</a> into the high timeframe range would provide an ideal entry point for bulls to step in. 
Currently, passive spot stacking has been observed between $100,000 and $104,000. 
If another breakout occurs, the focus will be on spot aggressively chasing bids and absorbing any sell walls.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43006771/bitcoin-up-to-99000-is-loving-inflation-data-release-xrp-dogecoin-follow-higher">Bitcoin Up To $99,000 &#8216;Is Loving&#8217; Inflation Data Release, XRP, Dogecoin Follow Higher</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

iShares Gold Trust Micro Shares

Interés en corto

iShares Gold Trust Micro Shares (ARCA:IAUM), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL